5 min read
Healthtech represents one of the fastest-growing segments in healthcare. Emerging technologies such as bioprinting, genomics, and smart devices are driving revolutionary advances in healthcare while presenting valuable investment opportunities. Some sources gauge the global market size at ~$350 billion in 2019 and project growth to reach $950 billion by 2027. The venture story is, not surprisingly, equally robust. There are ~20,000 healthtech startups in the U.S., and VCs invested about $14 billion into the sector in 2020 — double 2019’s total.
Some of this growth is due to the fact that consumers are increasingly embracing proactive, preventative, and personalized care, as well as self-monitoring products. Additionally, high healthcare costs are also increasing the demand for disruptive solutions. The global pandemic and the emergence of chronic diseases are also spurring innovation in telehealth and biotech.
Alumni Ventures’ Healthtech Fund will target this intersection of entrepreneurship, growing trends, and transformative medical advances to source high-potential opportunities for investors. We spoke with Alumni Ventures’ Chief Investment Officer Anton Simunovic about what investors can expect from AV’s Healthtech Fund.
by AV Communications Team